Last Updated: 23/01/2024
Malaria vaccine technology roadmap
Bill & Melinda Gates Foundation (BMGF), United States; European and Developing Countries Clinical Trials Partnership (EDCTP), The Netherlands; European Vaccine Initiative (EVI), Germany; European Commission, Belgium; PATH, United States; National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), United States; Wellcome Trust, United Kingdom; World Health Organization (WHO), Switzerland
Published: 01/11/2013
Malaria vaccine technology roadmap
Vision: Safe and effective vaccines against Plasmodium falciparum and Plasmodium vivax that prevent disease and death and prevent transmission to enable malaria eradication.
Strategic goals: By 2030, license vaccines targeting Plasmodium falciparum and Plasmodium vivax that encompass the following two objectives, for use by the international public health community:
- Development of malaria vaccines with protective efficacy of at least 75 percent against clinical malaria suitable for administration to appropriate at-risk groups in malaria endemic areas.
- Development of malaria vaccines that reduce transmission of the parasite and thereby substantially reduce the incidence of human malaria infection. This will enable elimination in multiple settings. Vaccines to reduce transmission should be suitable for administration in mass campaigns.
Related Projects
Array ( [0] => 20964 )
